Pfizer to buy back Akrimax plant and sell or close it by 2013
US drug giant Pfizer has exercised its option to re-acquire a manufacturing facility in Rouses Point, New York from Akrimax.
Pfizer, Roche and GSK report 2009 results
In a busy week of Big Phama results Pfizer reports sales boost from Wyeth, Roche says Genentech hit profits and GSK unveils surge in Relenza sales and plans to expand R&D restructuring.
Wyeth partners with Santaris on RNA development
Wyeth Pharmaceuticals is continuing efforts to improve its capabilities in the formulation and delivery of RNA through a strategic partnership with Santaris Pharma.
Akrimax wins first manufacturing contract
Akrimax Pharmaceuticals, which entered the contract manufacturing sector via the purchase of a Wyeth facility in New York, US, a year ago - has signed its first third-party agreement.
Wyeth launches $1.35bn bid for Crucell
Wyeth is in discussions to acquire vaccine manufacturer Crucell, in a deal that media reports suggest could be valued at more than $1.35bn.
Court finds Wyeth liable for generic’s harm
A Californian appeals court ruling may have altered product liability in the state, which could lead to numerous court cases being brought against big pharma.
Wyeth wields the axe again
Wyeth is to axe 1200 jobs in addition to the similar number it
earmarked for elimination only a month ago.
Wyeth cuts 1200 sales reps
1200 sales representatives are the latest casualties of Wyeth's
recently announced cost cutting drive, which strives to eliminate
10 per cent of the work force - 5,000 jobs - over the next three
Wyeth warns of job cut woes
Wyeth is the latest big pharma firm to warn that major job cuts are
on the cards, amidst a series of drug approval setbacks and generic
erosion on profits.
Wyeth site rescued by new start-up firm
Wyeth's manufacturing facility in Rouses Point, New York, has been
spared the scrap heap, with yesterday's announcement that new
pharma player Akrimax has bought up the beleaguered site.
Revamped Wyeth drug gets EU go-ahead
An improved version of Wyeth's haemophilia B treatment BeneFix -
the only recombinant Factor IX product available on the market -
kitted out with a host of new user-friendly features, has been
approved in the EU.
Wyeth facility gets FDA OK
The US Food and Drug Administration (FDA) has given Wyeth's Puerto
Rico manufacturing facility the all clear following a recent
re-inspection of the plant.
Merck, Pfizer, Sanofi-Aventis and Wyeth - People on the move
Merck, Pfizer, Sanofi-Aventis and Wyeth have all had people on the
move in the world of pharmaceutical manufacturing.
Wyeth boosts pipeline with three deals
Wyeth Pharmaceuticals is expanding its research into small
molecules schizophrenia drugs and biopharmaceuticals to treat
haemophilia, having announced three deals in a day earlier this
FDA to settle Citizen's Petitions against Wyeth
US Food and Drug Administration (FDA) has until April 2007 to reply
to a Citizen's Petition (CP) filed by Orchid Chemicals in response
to accusations of 'evergreening' related to Wyeth's re-formulated